Manas AI, a full-stack, AI-driven company focused on discovering and advancing next-generation medicines, announced the appointment of Jonathan Baell, PhD, as Chief Scientific Officer (CSO). Dr. Baell brings over 20 years of experience in drug discovery and development as a world-renowned medicinal chemist, and will lead the company’s scientific strategy and research initiatives.
Dr. Baell’s career includes serving as Executive Director of Discovery Chemistry at Lyterian Therapeutics, where he directed innovative drug discovery programs across multiple therapeutic areas. He previously founded and directed the Australian Translational Medicinal Chemistry Facility (ATMCF), developing it into a multimillion-dollar operation that spawned multiple spin-out companies and licensing agreements. His scientific achievements encompass discoveries in anti-cancer BCL2-family inhibitors and anti-anxiety GPCR modulators. He is recognized as the creator of PAINS (Pan Assay Interference Compounds), a framework that transformed scientific practices. His credentials include over 80 patents, 200 publications, and 15,000 citations.
CEO Dr. Siddhartha Mukherjee stated: “Dr. Baell’s groundbreaking contributions to medicinal chemistry and drug discovery, coupled with his visionary leadership, align perfectly with our mission to revolutionize therapeutics through AI-driven innovation.”
Dr. Baell responded: “Joining Manas AI feels like a perfect alignment of the stars. My experience and skills seamlessly complement the company’s aspirations.”
Dr. Baell holds positions as Senior Editor of “Future Medicinal Chemistry” and Chair of the Board of the International Chemical Biology Society, while serving on advisory boards for multiple biotechnology firms.